University of Notre Dame: Research to Revenue

University of Notre Dame

Summit Venture Studio

Research to Revenue Report

Summit Venture Studio (SVS) Opportunities

SVS has identified 0 commercialization opportunities from University of Notre Dame and scored them based on our proprietary metrics and rubrics.

The SVS model is to identify the top 1% of commercialization opportunities and start companies around them.

Please connect with SVS if you would like to engage with us in our startup and investment efforts.

Return on Research (ROR) Analysis

Commercialization Revenue per Research Dollar

Top Universities by Return on Research (ROR)

ROI Ratio: Commercialization Revenue ÷ Research Funding

University Innovation Analysis

Total Innovation Scores by Institution

Top Universities by Innovation Score

180+ High Innovation

150-179 Strong Innovation

130-149 Moderate Innovation

100-129 Emerging Innovation

130+ total score considered high innovation impact

SVS Innovation Index

Proprietary Assessment of University of Notre Dame's Innovation Ecosystem
Score out of 100. Benchmark: Top 50 U.S. research institutions.
A score of 90/100 can be read "doing better than 90% of schools benchmarked"

Innovation Visibility

68/100

Definition: Media mentions, publication count, and global research visibility metrics

Startup Momentum

7/100

Definition: Growth in patents, funding, and startup formation

Ecosystem Strength

72/100

Definition: Tech transfer infrastructure and support systems

Innovation Legacy

A Timeline of Groundbreaking Discoveries

Innovation Timeline

Founded

1842

First Nobel

1936

First Patent

1921

First IPO

2006

2022-2024

AI-powered medical device

2025

Today

Notable Commercialization Outcomes

Nobel Prizes

1980s

Antibody Patent

First antibody patent granted

1980s

Spin-off Launch

Invented medical device company

1995

Energy Tech

Developed biofuel technology

2004

Software License

Commercialized analytics software

2012

Biotech Breakthrough

Advanced cancer therapy patent

2017

Competitive Benchmarking

University of Notre Dame vs. Peer Research Universities

University of Notre Dame vs Peers Comparison

Metric	University of Notre Dame (FY2023)	Peer Average	Elite Average
Annual R&D Expenditure	$332M	$855M	$1,675M
New Inventions Disclosed	6	200	400
Startups Formed	2	7	10
Visibility Index	12	12	23
Licensing Revenue	$5M	$17M	$46M

Note: Peer Average = Median value among U.S. R1 research universities. Elite Average = Top 10 ranked U.S. research universities.

Emerging Opportunities

1. AI-Driven Cancer Diagnostics Revolutionizing Early Detection and Treatment

Notre Dame’s AI technology improves early cancer diagnosis accuracy, addressing critical delays in treatment, enhancing patient outcomes, and offering scalable healthcare solutions globally.

2. Sustainable Energy Storage Innovations Transforming Renewable Power Integration

Notre Dame’s advanced battery materials enable efficient, cost-effective energy storage, solving renewable intermittency issues and accelerating clean energy adoption worldwide.

3. Biodegradable Polymers for Eco-Friendly Packaging Solutions

Notre Dame develops scalable, sustainable biodegradable plastics reducing environmental pollution, meeting growing regulatory demands, and tapping into the expanding green packaging market.

4. Next-Generation Quantum Computing Algorithms Enhancing Cybersecurity

Notre Dame’s quantum algorithm research offers superior encryption methods, addressing rising cyber threats with scalable, cutting-edge technology for global digital security markets.

5. Precision Agriculture Technologies Boosting Crop Yields Sustainably

Notre Dame’s sensor and data analytics platform optimizes resource use, improving crop productivity and sustainability, meeting global food security challenges with scalable farming solutions.

6. Advanced Neuroscience Tools for Brain Disease Diagnosis and Treatment

Notre Dame’s innovative neuroimaging and biomarker technologies enable early detection and personalized therapy for neurological disorders, addressing significant unmet medical needs with scalable applications.